Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients

뉴스 본문을 불러오고 있어요.

Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients | 웨이프 WAPE

Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients

기사 요약

관련 종목

댓글 —